FIELD: medicine; oncology.
SUBSTANCE: invention can be used for treating breast cancer, positive by mutant estrogen receptor alpha. Method involves administering a therapeutically effective amount of a RAD1901 of the following structure (I):
.
EFFECT: use of the invention enables higher inhibition of tumor growth and provides its regression.
16 cl, 16 tbl, 42 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCER | 2019 |
|
RU2841076C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
